A Phase I/II Clinical Trial of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in the Treatment of Advanced Solid Tumors.
An Open-label, Multicenter Phase I/II Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SYS6043 Monotherapy or SYS6043 Combined With PD-1/VEGF Bispecific Antibody ± Chemotherapy in Patients With Advanced Solid Tumors.
This is a multicenter phase 1/2 clinical study to evaluate the efficacy and safety of SYS6043 monotherapy or SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy in patients with advanced solid tumors.
研究概览
地位
条件
详细说明
The Phase I study is a a dose-escalation study, comprises dose escalation for the doublet regimen and dose escalation for the triplet regimen. The Phase II study isa cohort expansion study.
Phase I: the dose escalation use a 3+3 design. The doublet regimen consists of SYS6043 + PD-1/VEGF bispecific antibody. The triplet regimen consists of SYS6043 combined with PD-1/VEGF bispecific antibody ± chemotherapy.
The Phase II study will be conducted as an expansion in 6 cohorts, with indications including triple-negative breast cancer, small cell lung cancer, non-small cell lung cancer, etc.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Jian Zhang
- 电话号码:021-64175590
- 邮箱:syner2000@163.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Be able to understand and voluntarily sign and datethe written ICF prior to any trial-related procedure;
- Age 18-75 (inclusive) years;
- Histologically or cytologically confirmed advanced/unresectable or metastatic solid tumors(specific cohort requirements apply, including TNBC, SCLC, and driver-gene negative NSCLC based on UICC/AJCC 8th edition staging);
- Dose escalation phase: evaluable lesions per RECIST v1.1. Dose expansion phase: at least one extracranial measurable lesion per RECIST v1.1. Lesions previously treated with radiotherapy or other local therapy may not be selected as target lesions unless there is clear evidence of progression.
- Qualified archived or fresh tumor tissue samples must be provided; participants who cannot provide tumor samples or whose samples are insufficient may be enrolled based on individual circumstances.
- Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1;
- Adequate organ and bone marrow function within 7 days prior to the first dose, as defined below.
- Life expectancy ≥ 3 months;
- Female participants of childbearing age must have a negative serum pregnancy test within 7 days before dosing. Male and female participants of reproductive potential must agree to use adequate contraception during the study and for at least 7 months after the last dose of the investigational product; during this period, female participants must not be breastfeeding, male participants must not freeze or donate sperm, and female participants must not donate eggs or undergo egg retrieval for personal use.
Exclusion Criteria:
- Combined SCLC (i.e., mixed large cell carcinoma, squamous cell carcinoma, spindle/pleomorphic and/or large cell components) and transformed SCLC.
- Prior history of CTCAE grade ≥3 immune-related adverse events (irAEs) during treatment with anti-PD-(L)1 or other immune checkpoint inhibitors, immune checkpoint agonists, immune cell therapy, or other therapies targeting tumor immune mechanisms, except for endocrine disorders such as hyperglycemia or hypothyroidism that have recovered to grade ≤2.
- Prior treatment with B7-H3-targeted therapies (including antibodies, antibody-drug conjugates [ADCs], chimeric antigen receptor T-cell [CAR-T] therapies, and other agents).
- Prior treatment with a topoisomerase I inhibitor antibody-drug conjugate or a topoisomerase I inhibitor.
- Toxicities from prior antitumor therapy have not resolved to CTCAE grade ≤1 or to the levels specified in the inclusion/exclusion criteria (except alopecia and hyperpigmentation).
- History of underlying pulmonary disease, including but not limited to severe asthma, severe COPD, restrictive lung disease, and other clinically significant pulmonary impairment or requirement for supplemental oxygen.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:SYS6043+PD-1/VEGF bispecific antibody
|
SYS6043: IV PD-1/VEGF bispecific antibody: IV |
|
实验性的:SYS6043 combined with PD-1/VEGF bispecific antibody +chemotherapy.
|
SYS6043: IV PD-1/VEGF bispecific antibody: IV Chemotherapy: cisplatin or carboplatin, IV |
|
实验性的:SYS6043 monotherapy
|
SYS6043: IV |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase I: Incidences of AEs
大体时间:From the signing of the informed consent form until 90 days after the last dose.
|
From the signing of the informed consent form until 90 days after the last dose.
|
|
|
Phase I: DLT
大体时间:21 days
|
Dose-limiting toxicity |
21 days
|
|
Phase I: MTD/RP2D
大体时间:After phase I dose escalation stage. Approximately 4 months.
|
Maximum Tolerated Dose/ Recommended Phase II Dose |
After phase I dose escalation stage. Approximately 4 months.
|
|
Phase II: ORR
大体时间:Up to 2 years
|
Objective response rate |
Up to 2 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase I: ORR
大体时间:Up to 2 years
|
Objective response rate |
Up to 2 years
|
|
Phase I:DCR
大体时间:Up to 2 years
|
Disease control rate |
Up to 2 years
|
|
Phase I:DOR
大体时间:Up to 2 years
|
Duration of response |
Up to 2 years
|
|
Phase I: TTR
大体时间:Up to 2 years
|
Time to Response |
Up to 2 years
|
|
Phase I: PFS
大体时间:Up to 2 years
|
Progression free survival |
Up to 2 years
|
|
Phase I:OS
大体时间:Up to 3 years
|
Overall survival |
Up to 3 years
|
|
Phase I:Plasma concentrations of SYS6043, total antibody, and free JS-1.
大体时间:Up to 2 years
|
Up to 2 years
|
|
|
Phase I:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
大体时间:Up to 2 years
|
Up to 2 years
|
|
|
Phase I:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
大体时间:Up to 2 years
|
Up to 2 years
|
|
|
Phase II:DCR
大体时间:Up to 2 years
|
Disease control rate |
Up to 2 years
|
|
Phase II:DOR
大体时间:Up to 2 years
|
Duration of response |
Up to 2 years
|
|
Phase II: TTR
大体时间:Up to 2 years
|
Time to Response |
Up to 2 years
|
|
Phase II: PFS
大体时间:Up to 2 years
|
Progression free survival |
Up to 2 years
|
|
Phase II:OS
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Title: Phase II: Incidences of AEs
大体时间:From the signing of the informed consent form until 90 days after the last dose.
|
Overall survival |
From the signing of the informed consent form until 90 days after the last dose.
|
|
Phase II:Plasma concentrations of SYS6043, total antibody, and free JS-1.
大体时间:Up to 2 years
|
Up to 2 years
|
|
|
Phase II:Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for SYS6043.
大体时间:Up to 2 years
|
Up to 2 years
|
|
|
Phase II:Expression levels of proteins such as B7-H3 and PD-L1 in tumor tissue.
大体时间:Up to 2 years
|
Up to 2 years
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- SYS6043-005
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.